CTOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

BioMarker Strategies

BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Piedmont Medical Laboratory

Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.